Here are three things to know:
- The analysis, which assessed the top 10 drugs with the largest net price increases, found that five of these drugs raised prices without new clinical evidence to justify the increases.
- Among the drugs with unsupported price hikes were Biktarvy, Darzalex, Xelijanz, Entresto and Cabometyx. These drugs saw price hikes ranging from 3.6% to 6.7% without demonstrating substantial improvements, according to the ICER report.
- While five drugs were found to have price increases with new clinical evidence — such as cancer treatments Keytruda and Opdivo — the unsupported increases contributed a total $815 million in additional spending for U.S. payers.
”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
